SLBT SPAC merger close and Nasdaq debut drive premarket momentum surge

 

• SL Science Holding (SLBT) completed business combination with SPAC Horizon Space Acquisition II (HSPT) on June 12, 2026; shares began trading on Nasdaq June 15 under new ticker.
• Biomedical firm focused on gamma delta T-cell therapies for cancer and exosome-based regenerative medicine; pre-revenue clinical-stage company saw high implied valuation post-deal.
• June 15 trading was highly volatile (range ~$3-14), closing ~$3.33 (-17% to -40%), followed by strong after-hours recovery over +120%.
• On June 16 premarket, SLBT surged ~118-244% amid exploding volume, appearing on multiple scanners as top momentum gainer alongside other small-caps.
• No new clinical data, partnerships, or company PR identified on June 16; move attributed to low-float de-SPAC dynamics, retail FOMO, and momentum trading.
• Typical post-listing volatility in biotech SPACs amplified by scanner alerts and social media chatter referencing it as a 'runner'.

https://finviz.com/stock?t=SLBT&p=d